INT162368

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.42
First Reported 2009
Last Reported 2010
Negated 0
Speculated 0
Reported most in Body
Documents 17
Total Number 18
Disease Relevance 7.96
Pain Relevance 3.34

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

signal transduction (Map3k8) cell cycle (Map3k8) kinase activity (Map3k8)
cytoplasm (Map3k8)
Anatomy Link Frequency
adipocytes 2
macrophage 1
Map3k8 (Mus musculus)
Pain Link Frequency Relevance Heat
imagery 1 99.08 Very High Very High Very High
cytokine 512 99.00 Very High Very High Very High
Inflammation 354 98.56 Very High Very High Very High
rheumatoid arthritis 2 98.28 Very High Very High Very High
Pain 53 96.44 Very High Very High Very High
Acupuncture 42 95.36 Very High Very High Very High
Kinase C 13 84.08 Quite High
Inflammatory stimuli 65 78.96 Quite High
Inflammatory mediators 26 78.88 Quite High
chemokine 3 75.68 Quite High
Disease Link Frequency Relevance Heat
Obesity 1378 99.64 Very High Very High Very High
INFLAMMATION 444 98.56 Very High Very High Very High
Rheumatoid Arthritis 2 98.28 Very High Very High Very High
Pain 66 96.44 Very High Very High Very High
Disease 17 96.40 Very High Very High Very High
Autoimmune Disease 2 95.44 Very High Very High Very High
Peritonitis 1 93.16 High High
Diabetes Mellitus 104 90.48 High High
Insulin Resistance 130 84.88 Quite High
Targeted Disruption 13 74.88 Quite High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Accordingly, Cot/tpl2 deficiency provoked a 25-30% reduction in luminol-mediated bioluminescence and neutrophil recruitment together with a 65% lower macrophage recruitment 4 h following zymosan-induced peritonitis.
Negative_regulation (deficiency) of Cot/tpl2 in macrophage associated with peritonitis
1) Confidence 0.42 Published 2010 Journal J. Biol. Chem. Section Abstract Doc Link 20736176 Disease Relevance 0.46 Pain Relevance 0.35
We showed that inhibition of Tpl2 markedly reduced IL-1?
Negative_regulation (inhibition) of Tpl2
2) Confidence 0.42 Published 2010 Journal Diabetes Section Body Doc Link PMC2797946 Disease Relevance 0.32 Pain Relevance 0.09
This review will describe the physiological regulation and importance of Cot/Tpl-2 in inflammation as well as the landscape of small molecules that have been reported as Cot/Tpl-2 inhibitors.
Negative_regulation (inhibitors) of Cot/Tpl-2 associated with inflammation
3) Confidence 0.42 Published 2009 Journal Curr Top Med Chem Section Abstract Doc Link 19689369 Disease Relevance 0.67 Pain Relevance 0.33
By inference, pharmaceutical agents that inhibit Cot/Tpl-2 kinase have the potential to be novel and effective therapies for the treatment of these diseases.
Negative_regulation (inhibit) of Cot/Tpl-2 associated with disease
4) Confidence 0.41 Published 2009 Journal Curr Top Med Chem Section Abstract Doc Link 19689369 Disease Relevance 0.71 Pain Relevance 0.36
However, Tpl2 inhibition did not totally block the lipolytic effect of TNF-?
Negative_regulation (inhibition) of Tpl2
5) Confidence 0.31 Published 2010 Journal Diabetes Section Body Doc Link PMC2797946 Disease Relevance 0.55 Pain Relevance 0.28
Transfection of siRNA against Tpl2 achieved >80% efficiency in reducing endogenous Tpl2 protein levels (Fig. 4A).
Negative_regulation (reducing) of Tpl2 protein
6) Confidence 0.31 Published 2010 Journal Diabetes Section Body Doc Link PMC2797946 Disease Relevance 0.22 Pain Relevance 0.25
Tpl2 inhibitor acts as a potent, reversible, and ATP-competitive inhibitor of Tpl2 with an IC50 of 50 nmol/l.
Negative_regulation (inhibitor) of Tpl2
7) Confidence 0.31 Published 2010 Journal Diabetes Section Body Doc Link PMC2797946 Disease Relevance 0.50 Pain Relevance 0.14
In human adipocytes, pharmacological inhibition of Tpl2 also inhibited ERK1/2 activation induced by IL-1?
Negative_regulation (inhibition) of Tpl2 in adipocytes associated with obesity
8) Confidence 0.31 Published 2010 Journal Diabetes Section Body Doc Link PMC2797946 Disease Relevance 0.27 Pain Relevance 0.10
Tpl2 inhibitor acts as a potent, reversible, and ATP-competitive inhibitor of Tpl2 with an IC50 of 50 nmol/l.
Negative_regulation (inhibitor) of Tpl2
9) Confidence 0.31 Published 2010 Journal Diabetes Section Body Doc Link PMC2797946 Disease Relevance 0.58 Pain Relevance 0.17
in adipocytes nearly suppressed the cytokine-induced MEK or ERK1/2 phosphorylation, whereas after inhibition of Tpl2, some phosphorylation remained.
Negative_regulation (inhibition) of Tpl2 in adipocytes associated with obesity and cytokine
10) Confidence 0.31 Published 2010 Journal Diabetes Section Body Doc Link PMC2797946 Disease Relevance 0.43 Pain Relevance 0.11
Tpl2 inhibition markedly blunted the effects of IL-1?
Negative_regulation (inhibition) of Tpl2
11) Confidence 0.31 Published 2010 Journal Diabetes Section Body Doc Link PMC2797946 Disease Relevance 0.42 Pain Relevance 0.09
Furthermore, compared with Tpl2 inhibitors, drugs that inhibit IKK?
Negative_regulation (inhibitors) of Tpl2
12) Confidence 0.31 Published 2010 Journal Diabetes Section Body Doc Link PMC2797946 Disease Relevance 0.81 Pain Relevance 0.12
This could be because siRNA knockdown or pharmacological inhibition of Tpl2 was not sufficient to completely shutdown Tpl2 activity.
Negative_regulation (shutdown) of Tpl2
13) Confidence 0.31 Published 2010 Journal Diabetes Section Body Doc Link PMC2797946 Disease Relevance 0.53 Pain Relevance 0.22
treatment was strongly prevented when cells were pretreated with the Tpl2 inhibitor (Fig. 3D and E).
Negative_regulation (inhibitor) of Tpl2
14) Confidence 0.31 Published 2010 Journal Diabetes Section Body Doc Link PMC2797946 Disease Relevance 0.29 Pain Relevance 0.19
According to this pattern one were supposed to have reduced EST, (from 3 to 2), and three of them that were supposed to report increased EST, from 4 to 5 and 6 to 7 respectively, after EA as compared with before EA.


Negative_regulation (reduced) of EST
15) Confidence 0.30 Published 2010 Journal Chin Med Section Body Doc Link PMC2942886 Disease Relevance 0.06 Pain Relevance 0.11
Tpl2 knockdown markedly decreased MEK and ERK1/2 phosphorylation induced by IL-1?
Negative_regulation (knockdown) of Tpl2
16) Confidence 0.27 Published 2010 Journal Diabetes Section Body Doc Link PMC2797946 Disease Relevance 0.27 Pain Relevance 0.25
MEK inhibition by U0126 treatment slightly decreased basal lipolysis and inhibited cytokines effect to a level comparable to the effect observed following Tpl2 inhibition (Fig. 5A and B). siRNA-mediated silencing of Tpl2 also reduced IL-1?
Negative_regulation (inhibition) of Tpl2 associated with cytokine
17) Confidence 0.27 Published 2010 Journal Diabetes Section Body Doc Link PMC2797946 Disease Relevance 0.86 Pain Relevance 0.15
EST increase was reported by 5 (23%) of the 22 women, unchanged by 11 (50%) and a decreased EST by the remaining 6 (27%) women.
Negative_regulation (decreased) of EST
18) Confidence 0.22 Published 2010 Journal Chin Med Section Body Doc Link PMC2942886 Disease Relevance 0 Pain Relevance 0.04

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox